2. Academic Validation
  3. Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence

Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence

  • Nat Biomed Eng. 2025 Oct 22. doi: 10.1038/s41551-025-01533-2.
Yannik Kaiser 1,  Christopher S Garris 1 2,  Eliana Marinari 3 4 5 6,  Hyung Shik Kim 1,  Juhyun Oh 1,  Martin Pedard 3 4 5 6,  Elias A Halabi 1,  Moonhyun Choi 1,  Sepideh Parvanian 1,  Rainer Kohler 1,  Denis Migliorini 3 4 5 6,  Ralph Weissleder 7 8
Affiliations

Affiliations

  • 1 Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
  • 2 Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • 3 Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.
  • 4 Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.
  • 5 Brain Tumor and Immune Cell Engineering Laboratory, AGORA Cancer Research Center, Lausanne, Switzerland.
  • 6 Swiss Cancer Center Léman (SCCL), Geneva, Switzerland.
  • 7 Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA. rweissleder@mgh.harvard.edu.
  • 8 Department of Systems Biology, Harvard Medical School, Boston, MA, USA. rweissleder@mgh.harvard.edu.
PMID: 41125869 DOI: 10.1038/s41551-025-01533-2
Abstract

Glioblastoma is a highly aggressive brain tumour with a high risk of recurrence after surgery, even when combined with chemotherapy and radiotherapy. A major barrier to lasting treatment is the tumour's immunosuppressive environment, which is largely dominated by myeloid cells. Here we describe the development of a biodegradable implant to sustainably release immune-modulator small molecules to reprogram tumour-infiltrating myeloid cells toward a pro-inflammatory, antitumour phenotype in the surgical cavity after tumour removal. In immunocompetent mouse models, this therapy induces interleukin-12 expression in myeloid cells without systemic cytokine elevation, and increases the infiltration of CD8+ and CD4+ T cells. Over 50% of mice treated (in combination with radiotherapy and chemotherapy) remain tumour-free during the experimental course (80 days). We further treated human glioblastoma explants ex vivo with the therapy and observed increased interleukin-12 expression in tumour-infiltrating myeloid cells, supporting the translational potential of this strategy. This implantable system offers a promising approach to prevent glioblastoma recurrence by activating innate immunity and sustaining immune surveillance post-surgery.

Figures
Products